echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > BMC Cancer: Hematologic changes in patients with unresectable stage III NSCLC receiving durvalumab maintenance therapy after cCRT

    BMC Cancer: Hematologic changes in patients with unresectable stage III NSCLC receiving durvalumab maintenance therapy after cCRT

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, a German team published a study in the journal BMC Cancer, mainly to study the hematological changes of durvalumab maintenance therapy after concurrent chemoradiotherapy (cCRT) in patients with stage III unresectable NSCLC
    .

    Recently, a German team published a study in the journal BMC Cancer, mainly to study the hematological changes of durvalumab maintenance therapy after concurrent chemoradiotherapy (cCRT) in patients with stage III unresectable NSCLC
    .


    NSCLC

    The study included 22 patients who completed platinum-based cCRT followed by durvalumab maintenance therapy
    .


    Analysis of parameters such as hemoglobin (Hb), leukocytes, lactate dehydrogenase (LDH), C-reactive protein (CRP), body weight, albumin before cCRT, after cCRT, and after starting durvalumab for 3, 6, 9, and 12 months changes


    The study included 22 patients who completed platinum-based cCRT followed by durvalumab maintenance therapy


    Of the 22 patients, 16 (72.


    During maintenance therapy, mean hemoglobin (Hb) increased by 1.


    Compared to initiation of durvalumab, LDH decreased by 29.
    86 U/l (11.
    74%) after 3 months (p = 0.
    022) and mean LDH decreased by 8.
    75 U/l (3.
    43%; p = 0.
    34) at 6 months, 9 It decreased by 11.
    95 U/l (4.
    76%) after one month (p = 0.
    26)
    .


    At the end of the 12-month observation period, mean LDH decreased by 36.


    Compared to initiation of durvalumab, LDH decreased by 29.


    CRP > 5 mg/dl was defined as CRP elevation based on all values ​​measured in the group
    .


    CRP was elevated in 1 patient (4.


    CRP > 5 mg/dl was defined as CRP elevation based on all values ​​measured in the group


    Median weight change [kg] after 12 months was +6.
    06% (range: 8.
    89 +18.
    75%)
    .


    Durvalumab cycles were significantly associated with total body weight gain [kg] (spearma-Rho correlation: r = 0.


    Median weight change [kg] after 12 months was +6.


    There were no significant changes in liver and kidney function
    .

    There were no significant changes in liver and kidney function
    .


    In conclusion, the study showed that in patients with unresectable stage III NSCLC who received durvalumab maintenance therapy after cCRT for 1 year, no serious hematological toxicity was observed in laboratory blood tests
    .
    Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
    .

    In conclusion, the study showed that in patients with unresectable stage III NSCLC who received durvalumab maintenance therapy after cCRT for 1 year, no serious hematological toxicity was observed in laboratory blood tests
    .
    Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
    .
    The study showed that in patients with unresectable stage III NSCLC who received durvalumab maintenance therapy after cCRT for 1 year, laboratory blood tests showed no serious hematologic toxicity
    .
    Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
    .
    The study showed that in patients with unresectable stage III NSCLC who received durvalumab maintenance therapy after cCRT for 1 year, laboratory blood tests showed no serious hematologic toxicity
    .
    Receiving at least 12 cycles of durvalumab appeared to have a significant effect on hemoglobin levels and weight recovery
    .

    Original source:

    Original source:

    J.
    Guggenberger, S.
    Kenndof, J.
    Taugner, et al.
    Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
    BMC Cancer (2022) 22:317.
    https: https://doi.
    org/10.
    1186/s12885-022-09395-6

    J.
    Guggenberger, S.
    Kenndof, J.
    Taugner, et al.
    Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
    BMC Cancer (2022) 22:317.
    https: https://doi.
    org/10.
    1186/s12885-022-09395-6

     

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.